PMID- 35769049
OWN - NLM
STAT- Publisher
LR  - 20240216
IS  - 1930-613X (Electronic)
IS  - 0026-4075 (Print)
IS  - 0026-4075 (Linking)
DP  - 2022 Jun 29
TI  - SARS-CoV-2 Antibody Longitudinal Profile of Immune Globulin Preparations.
LID - 10.1093/milmed/usac192 [doi]
LID - usac192
AB  - INTRODUCTION: Intravenous immunoglobulin (IVIG) preparations, used for the 
      treatment of antibody deficiencies, provide a glimpse of the general population's 
      antibody profile as each preparation is generated from a pool of thousands of 
      donors. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 
      virus responsible for the coronavirus disease 2019 (Covid-19) pandemic, and a 
      vaccine for the prevention of Covid-19 was authorized for emergency use in 
      December 2020. We completed a longitudinal analysis of SARS-CoV-2 antibody levels 
      in commercial IVIG preparations. MATERIALS AND METHODS: We collected IVIG samples 
      from our infusion clinic. IVIG product lot number, product name, and manufacturer 
      information were recorded, with the date of preparation verified from the 
      manufacturer. SARS-CoV-2 antibody titers as well as total immunoglobulin levels 
      were measured using commercially available assays. The study received 
      Institutional Review Board approval. RESULTS: We found no SARS-CoV-2 antibodies 
      in preparations generated on or before January 2020. Overall, SARS-CoV-2 antibody 
      levels in IVIG preparations tended to increase with progressing preparation date. 
      We observed a dramatic and continual rise of SARS-CoV-2 antibody levels in IVIG 
      preparations made in the beginning after January 2021, coinciding with the peak 
      in incidence of confirmed cases and availability of Covid-19 vaccines in the 
      United States. CONCLUSION: SARS-CoV-2 antibody levels in IVIG mirror case 
      prevalence, and vaccination resulted in a far more rapid rate of rise in antibody 
      levels. IVIG preparations or serum repositories can provide an accessible way to 
      model a population's evolving novel pathogen exposure, immunity, and vaccine 
      response.
CI  - Published by Oxford University Press on behalf of the Association of Military 
      Surgeons of the United States 2022. This work is written by (a) US Government 
      employee(s) and is in the public domain in the US.
FAU - Park, Hyun J
AU  - Park HJ
AD  - Department of Allergy and Immunology, Walter Reed National Military Medical 
      Center, Bethesda, MD 20892, USA.
FAU - Alcover, Karl C
AU  - Alcover KC
AD  - Department of Medicine, Uniformed Services University of the Health Sciences, 
      Bethesda, MD 20814, USA.
FAU - Wang, Qing
AU  - Wang Q
AD  - Department of Allergy and Immunology, Walter Reed National Military Medical 
      Center, Bethesda, MD 20892, USA.
FAU - Gada, Satyen M
AU  - Gada SM
AD  - Department of Allergy and Immunology, Walter Reed National Military Medical 
      Center, Bethesda, MD 20892, USA.
LA  - eng
GR  - DRP - Graduate Medical Education Research Funding/Walter Reed National Military 
      Medical Center/
PT  - Journal Article
DEP - 20220629
PL  - England
TA  - Mil Med
JT  - Military medicine
JID - 2984771R
SB  - IM
PMC - PMC9384366
EDAT- 2022/07/01 06:00
MHDA- 2022/07/01 06:00
PMCR- 2022/06/29
CRDT- 2022/06/30 02:23
PHST- 2022/04/05 00:00 [received]
PHST- 2022/05/16 00:00 [revised]
PHST- 2022/06/16 00:00 [accepted]
PHST- 2022/06/30 02:23 [entrez]
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/07/01 06:00 [medline]
PHST- 2022/06/29 00:00 [pmc-release]
AID - 6619607 [pii]
AID - usac192 [pii]
AID - 10.1093/milmed/usac192 [doi]
PST - aheadofprint
SO  - Mil Med. 2022 Jun 29:usac192. doi: 10.1093/milmed/usac192.